Clinical Updatesbone mineral densityosteoporosis
Optimizing Anabolic Therapy: A Comparative Analysis of 3-Month vs. 12-Month Romosozumab Regimens in Postmenopausal Osteoporosis
By MedXY|Mar 10, 2026
This review analyzes the LIDA trial findings, demonstrating that an abbreviated 3-month romosozumab course followed by denosumab is non-inferior to the standard 12-month regimen in increasing total hip bone mineral density, potentially redu
